Approval · Notice of Compliance 25912 · 2021
APIDRA: Notice of Compliance 25912
Issued May 18, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25912
- Date
- May 18, 2021
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| APIDRA | Not yet assigned | — |
Medicinal ingredients
- INSULIN GLULISINE (RECOMBINANT DNA ORIGIN) 100 UNIT per ML